Organon Analysts Lower Their Forecasts Following Q3 Outcomes – Organon (NYSE:OGN)

Organon (NYSE:OGN) reported better-than-expected earnings for the third quarter on Monday.

The corporate posted third-quarter adjusted earnings of $1.01 per share on Monday, beating the consensus estimate of 94 cents. The worldwide healthcare firm reported quarterly gross sales of $1.602 billion, beating the Wall Road estimate of $1.56 billion.

Organon lowered its fiscal gross sales steering from $6.275 billion-$6.375 billion to $6.20 billion-$6.25 billion, beneath the consensus of $6.289 billion.

“I’m humbled to be working alongside our proficient workforce throughout this pivotal time for Organon,” stated Joe Morrissey, Organon’s Interim Chief Govt Officer. “We’re harnessing the corporate’s many strengths, together with a various portfolio that we count on will generate greater than $900 million in free money move earlier than one-time prices this 12 months. We additionally stay dedicated to exercising price self-discipline and decreasing our debt burden proactively, the place doable. These actions will create further steadiness sheet capability, positioning us to pursue future development alternatives in ladies’s well being and additional our mission to ship impactful medicines and options for a more healthy every single day.”

Organon shares fell 3.4% to commerce at $7.44 on Tuesday.

These analysts made modifications to their worth targets on Organon following earnings announcement.

• Morgan Stanley analyst Terence Flynn maintained Organon with an Equal-Weight score and lowered the value goal from $10 to $9.
• JP Morgan analyst Chris Schott maintained the inventory with an Underweight score and reduce the value goal from $14 to $12.

Contemplating shopping for OGN inventory? Right here’s what analysts assume:

Learn This Subsequent:

Photograph by way of Shutterstock